Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “TP53”

201 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 201 results

Testing effectiveness (Phase 2)Study completedNCT00617409
What this trial is testing

To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid

Who this might be right for
Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 69
Testing effectiveness (Phase 2)WithdrawnNCT06690281
What this trial is testing

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Who this might be right for
Gastrointestinal CarcinomaPancreatic CancerHepatocellular Cancer+5 more
National Cancer Institute (NCI)
Not applicableStudy completedNCT02309567
What this trial is testing

Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?

Who this might be right for
Lung NeoplasmsGene, p53
Cumhuriyet University 146
Testing effectiveness (Phase 2)Active Not RecruitingNCT05180695
What this trial is testing

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

Who this might be right for
Advanced Soft-tissue SarcomaMetastatic Soft-tissue Sarcoma
Centre Leon Berard 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT03641313
What this trial is testing

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+5 more
National Cancer Institute (NCI) 17
Testing effectiveness (Phase 2)Ended earlyNCT02449655
What this trial is testing

Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

Who this might be right for
Advanced Gastric Adenocarcinoma
Samsung Medical Center 27
Testing effectiveness (Phase 2)Study completedNCT01914900
What this trial is testing

Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer

Who this might be right for
Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 14
Not applicableStudy completedNCT04452292
What this trial is testing

Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma

Who this might be right for
Large-Cell Neuroendocrine Carcinoma
Charles Kunos 2
Testing effectiveness (Phase 2)Ended earlyNCT02688907
What this trial is testing

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Who this might be right for
Small Cell Lung Cancer
Samsung Medical Center 7
Early research (Phase 1)Ended earlyNCT04638309
What this trial is testing

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Who this might be right for
MDSMyelodysplastic Syndromes
Aprea Therapeutics 4
Testing effectiveness (Phase 2)WithdrawnNCT06090318
What this trial is testing

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Who this might be right for
Advanced Solid TumorCDKN2ANSCLC+7 more
Rain Oncology Inc
Early research (Phase 1)Not Yet RecruitingNCT07511062
What this trial is testing

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

Who this might be right for
Acute Myeloid LeukemiaTP53 Gene Mutation
Northside Hospital, Inc. 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT05491811
What this trial is testing

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 49
Testing effectiveness (Phase 2)UnknownNCT05932264
What this trial is testing

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Who this might be right for
NSCLCNon-small Cell Lung Cancer
Sun Yat-sen University 60
Early research (Phase 1)Ended earlyNCT03975387
What this trial is testing

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Who this might be right for
Solid Tumor
Taiho Oncology, Inc. 106
Not applicableUnknownNCT04489706
What this trial is testing

Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation

Who this might be right for
Ovarian CancerEndometrial Cancer
Ruijin Hospital 20
Testing effectiveness (Phase 2)Study completedNCT02758665
What this trial is testing

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Who this might be right for
Leukemia, Lymphocytic, Chronic
University of Ulm 41
Testing effectiveness (Phase 2)Study completedNCT02797977
What this trial is testing

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Who this might be right for
Advanced Solid Tumors
Sierra Oncology LLC - a GSK company 153
Not applicableLooking for participantsNCT06791941
What this trial is testing

Study of the Contribution of Mutant p53/YAP Proteins to Therapy Resistance in Recurrent Head and Neck Cancer

Who this might be right for
Head and Neck Tumors
Regina Elena Cancer Institute 18
Testing effectiveness (Phase 2)Ended earlyNCT03063203
What this trial is testing

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia, Relapsed, Adult
Washington University School of Medicine 17
Load More Results